LAPTM5 and Venetoclax Resistance in Multiple Myeloma
Author Information
Author(s): Li Yuxiang, Bai Jing, Liu Dan, Hao Jinxia, Yan Ruyu, Guo Hongjuan, Huang Yuzhi, Yu Hongtao, Leng Hao, Zhou Kecheng, Liu Minxia
Primary Institution: Anhui Medical University
Hypothesis
This study investigates the role of LAPTM5 in conferring resistance to venetoclax in relapsed multiple myeloma.
Conclusion
LAPTM5 enhances autophagy and contributes to venetoclax resistance in multiple myeloma cells.
Supporting Evidence
- LAPTM5 is upregulated in relapsed multiple myeloma cells.
- LAPTM5 enhances autophagic flux, which is crucial for cell survival under therapeutic stress.
- Knockdown of LAPTM5 increases sensitivity to venetoclax in resistant cell lines.
- Overexpression of LAPTM5 promotes resistance to venetoclax.
- LAPTM5 facilitates the fusion of autophagosomes with lysosomes.
Takeaway
LAPTM5 helps cancer cells survive against a drug called venetoclax by boosting a process called autophagy, which helps the cells recycle and manage their waste.
Methodology
The study used cell lines, patient tissue analyses, and bioinformatics to assess LAPTM5 expression and its role in drug resistance.
Limitations
The study primarily focuses on LAPTM5 without exploring other potential factors influencing drug resistance.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website